Find clinical trials for Leukemia in Warszawa, Mazowieckie
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Leukemia trials near Warszawa, Mazowieckie, POL:
This first-in-human study will evaluate RVU120 (SEL120), a novel small molecule CDK8/19 inhibitor, in patients with Acute Myeloid Leukemia (...
Phase 1
Warsaw, Poland and 9 other locations
of the study is to characterize safety and tolerability of cusatuzumab in combination with various therapies used to treat acute myeloid leukemia...
Phase 1
Warszawa, Poland and 22 other locations
clinical evaluation of ELVN-001 in patients with chronic myeloid leukemia with and without T315I mutations in patients who are relapsed, ref...
Phase 1
Warszawa, Poland and 45 other locations
The purpose of the study is to optimize the treatment of asciminib in patients with chronic myelogenous leukemia in chronic phase (CML-CP) p...
Phase 3
Warsaw, Poland and 47 other locations
study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia...
Phase 3
Warsaw, Poland and 207 other locations
chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia...
Phase 3
Warsaw, Poland and 275 other locations
Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed orig...
Phase 4
Warsaw, Poland and 34 other locations
The purpose of this study is to compare the efficacy and safety of pirtobrutinib (LOXO-305; Arm A) compared to BR (Arm B) in patients with CLL/SLL wh...
Phase 3
Warsaw, Poland and 107 other locations
Researchers are looking for new ways to treat people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SL...
Phase 3
Warszawa, Mazowieckie, Poland and 98 other locations
The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzum...
Phase 3
Warsaw, Poland and 87 other locations
Clinical trials
Research sites
Resources
Legal